Can Synthesis Impurities in Calcitonin Peptide Drugs Trigger Immune Reactions?

Some impurities generated during salmon calcitonin peptide synthesis showed potential to bind immune molecules and stimulate T cells, posing immunogenicity risk.

Roberts, Brian J et al.·Frontiers in pharmacology·2024·Preliminary Evidencein vitro
RPEP-09158In vitroPreliminary Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in vitro
Evidence
Preliminary Evidence
Sample
In silico and in vitro immunogenicity assessment of peptide impurities
Participants
In silico and in vitro immunogenicity assessment of peptide impurities

What This Study Found

Certain synthesis-derived impurities of salmon calcitonin showed potential to bind HLA molecules and stimulate T cells, indicating immunogenicity risk that warrants monitoring.

Key Numbers

Impurities included amino acid insertions, deletions, and side-chain modifications from the synthesis process.

How They Did This

Combined computational (in silico) prediction with in vitro HLA binding and T-cell stimulation assays to assess immunogenicity of peptide impurities.

Why This Research Matters

As more peptide drugs shift from biological to chemical manufacturing, understanding whether new impurities can trigger immune reactions is essential for drug safety.

The Bigger Picture

More peptide drugs are being manufactured by chemical synthesis instead of biological production. Understanding the immunogenicity risk of synthesis-related impurities is essential for ensuring generic and biosimilar peptide drug safety.

What This Study Doesn't Tell Us

In silico and in vitro methods can predict immunogenicity risk but cannot confirm actual clinical immune reactions. In vivo validation would be needed.

Questions This Raises

  • ?Should immunogenicity testing be mandatory for all chemically synthesized peptide drugs?
  • ?Do these impurities accumulate at clinically relevant levels?

Trust & Context

Key Stat:
T-cell stimulation detected Certain synthesis byproducts of salmon calcitonin showed the ability to activate immune T cells in laboratory assays
Evidence Grade:
Rated preliminary: combined computational and in vitro assessment identifying risk, but clinical significance needs in vivo confirmation.
Study Age:
Published in 2024. Timely as more peptide drugs (especially GLP-1 drugs) shift to chemical synthesis manufacturing.
Original Title:
Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods.
Published In:
Frontiers in pharmacology, 15, 1363139 (2024)
Database ID:
RPEP-09158

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What are peptide drug impurities?

Manufacturing byproducts where amino acids are inserted, deleted, or modified, creating slightly different molecules from the intended drug.

Can impurities in peptide drugs cause allergic reactions?

This study shows some impurities can potentially activate immune cells. Whether this translates to clinical reactions needs further investigation.

Read More on RethinkPeptides

Cite This Study

RPEP-09158·https://rethinkpeptides.com/research/RPEP-09158

APA

Roberts, Brian J; Mattei, Aimee E; Howard, Kristina E; Weaver, James L; Liu, Hao; Lelias, Sandra; Martin, William D; Verthelyi, Daniela; Pang, Eric; Edwards, Katie J; De Groot, Anne S. (2024). Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods.. Frontiers in pharmacology, 15, 1363139. https://doi.org/10.3389/fphar.2024.1363139

MLA

Roberts, Brian J, et al. "Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods.." Frontiers in pharmacology, 2024. https://doi.org/10.3389/fphar.2024.1363139

RethinkPeptides

RethinkPeptides Research Database. "Assessing the immunogenicity risk of salmon calcitonin pepti..." RPEP-09158. Retrieved from https://rethinkpeptides.com/research/roberts-2024-assessing-the-immunogenicity-risk

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.